Sentences with phrase «synucleinopathy of»

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez - Torres E, Hallett PJ, Isacson O. Glucocerebrosidase gene therapy prevents α - synucleinopathy of midbrain dopamine neurons.

«Our findings contribute important new evidence about the natural history and survival of people affected by synucleinopathies of various types.

As recently as two years ago, there was little evidence of any academic or biotech industry interest in pursuing clearance of AS as a therapeutic approach to PD, LBD, or other synucleinopathies of aging: after a promising 2005 report, [31] there had been virtual silence.

Not exact matches

The population - based study by Rodolfo Savica, M.D., Ph.D., and coauthors of the Mayo Clinic, Rochester Minn., included all the residents of Minnesota's Olmsted County and identified 461 patients with synucleinopathies and 452 patients without for comparison.

Of the 461 patients with synucleinopathies, 316 (68.6 percent) died during follow - up, while among the 452 participants used for comparison, 220 (48.7 percent) died during follow - up.

«New clues on the base of Parkinson's disease, other «synucleinopathies».»

The test could enable earlier diagnosis of a group of degenerative brain diseases called synucleinopathies, which include Parkinson's disease, Lewy Body dementia, and multiple system atrophy.

«This study shows that researchers working on problems in rare diseases, such as blood pressure in synucleinopathies, can pool together data and ideas and develop a simple bedside test that can perhaps help spot these problems earlier,» says Dr. Kaufmann, the Felicia B. Axelrod Professor of Dysautonomia Research in the Department of Neurology, and professor of medicine and pediatrics at NYU School of Medicine.

Although several large studies have shown that α - synuclein levels are lower in the CSF of PD patients and those with related synucleinopathies compared to controls, its role in cognitive decline and dementia had been unexplored.

Yet if you look at people who develop the clinical syndrome of dementia, especially later in life, yes, they have amyloid in the brain but they also have other pathologic entities — vascular disease; synucleinopathies [insoluble fibrils of the normally soluble protein, alpha - synuclein]; a tauopathy [which is marked by disease - inducing, insoluble tangles of another protein, tau].

Roche and Prothena will collaborate on the development of PRX002 for Parkinson's disease and potentially other synucleinopathies.

Lewy bodies (LB) and other intracellular α - synuclein (AS) aggregates accumulate in the aging nervous system, and a high burden of such aggregates are hallmark neuropathological signs of Parkinson's disease (PD), Lewy body dementia (LBD), multiple systems atrophy (MSA), and other synucleinopathies.

In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies in animal models of human synucleinopathies.

The clinical consortium is led by AFFiRiS itself, and in addition to the PD booster trial, it is now recruiting for a separate Phase I trial of the α - synuclein vaccine against MSA, a synucleinopathy differentiated from PD or LBD based on the cell populations affected, the regional concentration of AS neuropathology, and the spectrum of movement and other symptoms.

One might speculate that each of these damage - repair therapeutics may exhibit differential targeting of particular AS species or brain regions, as different clinical synucleinopathies exhibit distinct regional localizations and conformations of AS pathology.

AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LBD than PD.

The company's antibody - based product candidates target a number of potential indications including AL and AA forms of amyloidosis, Parkinson's disease and other related synucleinopathies and novel cell adhesion targets involved in inflammatory diseases and cancers.

The therapies have a broad range of indications including Parkinson's disease and related synucleinopathies.